HEMATOLOGY

In closing the discussion, Dr Mascarenhas shares clinical pearls for community oncologists treating patients with myelofibrosis.

John Mascarenhas, MD, looks to the future of myelofibrosis treatment, noting present challenges and treatment strategies in development that may address those unmet needs.

Focusing on the safety profiles of JAK2 inhibitors, a myelofibrosis specialist discusses the adverse events encountered with pacritinib, ruxolitinib, and momelotinib.

John Mascarenhas, MD, reviews JAK2 inhibitor options for patients with myelofibrosis, including pacritinib, ruxolitinib, and momelotinib.

An expert on myelofibrosis discusses clinical studies investigating pacritinib, including data from the latest survival analysis of the PERSIST-2 clinical trial.

A hematologist-oncologist gives an overview of the treatment of myelofibrosis by defining the disease and highlighting biological pathways, therapeutic options, and factors that drive treatment selection.

John O. Mascarenhas, MD, presents the case of a 62-year-old man with myelofibrosis and provides clinical insights on treatment decisions.

Musa Yilmaz, MD, discusses the most recent update of the phase 1/2 study of quizartinib, venetoclax, and decitabine in FLT3-internal tandem duplication mutated acute myeloid leukemia and the background behind this research.

Stephanie Lee, MD, discusses a study investigating belumosudil for chronic graft-vs-host disease.

Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.

Jeremy Ramdial, MD, discussed a phase 1/2 study investigating the GemCloBu conditioning regimen for stem cell transplants in aggressive lymphomas.

In an interview with Targeted Oncology, Claire Saxton, MBA, and Ashley Moncrief, discussed the importance of education efforts focused on ensuring that patients with MDS understand their diagnosis and options so that they can make informed decisions about their care.

Ropeginterferon alfa is now a recommended first-line treatment for patients with polycythemia vera, according to the National Comprehensive Cancer Network’s updated guidelines.

In the second article of a 2-part series, Lori Muffly, MD, MS, leads a discussion on how treatment considerations change when a patient has severe graft-vs-host disease or if the involvement is in the lung and where ruxolitinib fits into treatment.

Promising survival data for Orca-T was also matched in a population of patients with hematologic malignancies aged 55 years and older.

The combination of belumosudil plus ruxolitinib demonstrated response and tolerability in patients with steroid-refractory or steroid-dependent chronic graft-vs-host disease.

Findings from an analysis of the REACH2 study, presented at the 2024 Transplantation & Cellular Therapy Meetings, showed that concomitant treatment with azoles does not impact the safety and efficacy of ruxolitinib for patients with acute graft-vs-host-disease.

A retrospective study of insurance claims showed patients received ruxolitinib mainly in the second or third line for chronic graft-vs-host disease, with dose adjustment used and no difference shown in time to discontinuation between adult and pediatric patients.

Ruxolitinib cream resulted in positive safety and efficacy findings among a small cohort of patients with cutaneous graft-vs-host disease vs placebo.

An orphan drug designation has been granted by the FDA for IO-202 as a treatment option for patients with chronic myelomonocytic leukemia.

The ruxolitinib and belumosudil combination demonstrated a 55% overall response rate in GVHD, suggesting synergy between inflammatory pathways. The combination was well-tolerated, delayed the need for other therapies.

Ongoing and future trials will attempt to demonstrate the benefi t of NK cell therapies in lymphomas, multiple myeloma, sarcomas, and glioblastoma multiforme, among others.

Following the FDA clearance of an investigational new drug application, a phase 1 trial will evaluate KME-0584 for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

Raajit K. Rampal, MD, PhD, discusses some of the key takeaways from the 2023 American Society of Hematology Annual Meeting and what he believes holds promise for the space in 2024.

Magrolimab will no longer be in development as a treatment option for patients with hematologic malignancies.